Vitamin D receptor: A highly versatile nuclear receptor

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Volume 69, Issue 1, Pages (January 2006)
V.M. Campese, N. Mitra, D. Sandee  Kidney International 
Beta blockers in the management of chronic kidney disease
Volume 67, Pages S1-S7 (June 2005)
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
Volume 82, Issue 1, Pages 7-8 (July 2012)
Renal vitamin D receptor expression and vitamin D renoprotection
Volume 79, Issue 9, Pages (May 2011)
Volume 83, Issue 3, Pages (March 2013)
New Vitamin D analogs and changing therapeutic paradigms
FGF23 or PTH: which comes first in CKD ?
Vitamin D deficiency and heart disease
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Shining light on vitamin D trials in chronic kidney disease
Ergocalciferol and Cholecalciferol in CKD
FGF23–parathyroid interaction: implications in chronic kidney disease
Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation  Adriana S. Dusso  Kidney International Supplements 
John P. Middleton, Patrick H. Pun  Kidney International 
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Chapter 3: Management of progression and complications of CKD
Volume 85, Issue 3, Pages (March 2014)
V.M. Campese, N. Mitra, D. Sandee  Kidney International 
Volume 72, Issue 6, Pages (September 2007)
Tally Naveh-Many, Justin Silver  Kidney International 
Volume 74, Issue 3, Pages (August 2008)
Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps  Vincent M. Brandenburg, Markus.
Volume 70, Issue 11, Pages (December 2006)
Volume 79, Pages S20-S23 (April 2011)
The need for reliable serum parathyroid hormone measurements
Gary C.W. Chan, Sydney C.W. Tang  Kidney International 
Volume 71, Issue 11, Pages (June 2007)
Use of vitamin D in chronic kidney disease patients
Florian Lang, Michael Föller  Kidney International 
Volume 75, Issue 11, Pages (June 2009)
Volume 71, Issue 6, Pages (March 2007)
Volume 70, Issue 12, Pages (December 2006)
Volume 68, Pages S24-S28 (July 2005)
Fructose intake as a risk factor for kidney stone disease
Volume 73, Issue 12, Pages (June 2008)
Volume 56, Pages S31-S37 (December 1999)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 87, Issue 3, Pages (March 2015)
Methods for guideline development
Atrial fibrillation in end-stage renal disease: an emerging problem
Volume 75, Issue 9, Pages (May 2009)
Fibroblast growth factor 23: the making of a hormone
Volume 56, Issue 4, Pages (October 1999)
Volume 69, Issue 11, Pages (June 2006)
Cardio-Kidney-Damage: a unifying concept
Phosphate and the parathyroid
Organ transplantation goes to the movies
Low triiodothyronine and survival in end-stage renal disease
Volume 72, Issue 2, Pages (July 2007)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
Volume 69, Issue 1, Pages (January 2006)
Is complement a target for therapy in renal disease?
Volume 70, Issue 3, Pages (August 2006)
Volume 71, Issue 9, Pages (May 2007)
Stephen G. Rostand, Tilman B. Drüeke  Kidney International 
Volume 75, Issue 7, Pages (April 2009)
T cells and T-cell receptors in acute renal failure
The ins and outs of phosphate homeostasis
In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression  B.O. Eriksen, O.C. Ingebretsen  Kidney.
Volume 74, Issue 10, Pages (November 2008)
Ronen Levi, Justin Silver  Kidney International 
Volume 86, Issue 2, Pages (August 2014)
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Vitamin D receptor: A highly versatile nuclear receptor J.R. Wu-Wong  Kidney International  Volume 72, Issue 3, Pages 237-239 (August 2007) DOI: 10.1038/sj.ki.5002428 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Hypothetical mechanisms for mortality related to cardiovascular disease in chronic kidney disease. Chronic kidney disease itself may affect many factors involved in regulation of mineral homeostasis, inflammation, thrombogenesis, vascular function, the renin–angiotensin–aldosterone system (RAAS), and the atrial natriuretic peptide/brain natriuretic peptide (ANP/BNP)–type A natriuretic peptide receptor (NPR-A) pathway. VDR may also play a key role in regulating several of these mechanisms. Kidney International 2007 72, 237-239DOI: (10.1038/sj.ki.5002428) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 2 VDR-mediated autocrine, endocrine, and paracrine effects. Calcitriol is well documented as an endocrine hormone. It may also work as an autocrine/paracrine factor in cardiovascular and other systems. Under normal conditions, many renal and extrarenal cells may be capable of generating calcitriol from 25(OH)D3. In chronic kidney disease (CKD), VDR-mediated endocrine, autocrine, and paracrine effects may be compromised. PTH, parathyroid hormone. Kidney International 2007 72, 237-239DOI: (10.1038/sj.ki.5002428) Copyright © 2007 International Society of Nephrology Terms and Conditions